First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer

Published:2021-03-18 Issue:3 Volume:2021 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Greenhalgh Janette¹,Boland Angela¹,Bates Victoria¹,Vecchio Fabio¹,Dundar Yenal¹²,Chaplin Marty³,Green John A⁴

Affiliation:

1. Liverpool Reviews and Implementation Group; University of Liverpool; Liverpool UK

2. Central Queensland Hospital and Health Service; Rockhampton Australia

3. Department of Clinical Sciences; Liverpool School of Tropical Medicine; Liverpool UK

4. Institute of Translational Medicine; University of Liverpool; Bebington UK

Publisher

Wiley

Subject

Pharmacology (medical)

Reference146 articles.

1. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer;Khambata-Ford;Journal of Clinical Oncology,2010

2. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small cell lung cancer: results of the randomized multicenter phase III trial BMS099;Lynch;Journal of Clinical Oncology,2010

3. Phase II randomized trial of erlotinib or vinorelbine in chemonaive, advanced, non-small cell lung cancer patients aged 70 years or older;Chen;Journal of Thoracic Oncology,2012

4. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study;Shi;Annals of Oncology,2017

5. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study;Zhou;Annals of Oncology,2015

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Estimating the replicability of highly cited clinical research (2004–2018);PLOS ONE;2024-08-07

2. Dihydroisotanshinone I regulates ferroptosis via PI3K/AKT pathway to enhance cisplatin sensitivity in lung adenocarcinoma;Journal of Pharmacy and Pharmacology;2024-07-23

3. Optimization of treatment strategies for elderly patients with advanced non-small cell lung cancer;Frontiers in Oncology;2024-07-16

4. Illness trajectories of incurable solid cancers;BMJ;2024-03-01

5. Genetic mutation profiling reveals biomarkers for targeted therapy efficacy and prognosis in non-small cell lung cancer;Heliyon;2024-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3